MedTrace Logo

Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy

NCT02795572 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2019-07-05

No results posted yet for this study

Summary

The trial will utilize Nutraceuticals (Vitamin D 2000IU oral once daily, Vitamin B6 100 mg oral once daily, Vitamin B12 100 mcg oral once daily, Omega-3 Fatty Acids 900 mg oral three times a day) in patients treated with Docetacel as Neoadjuvant or Adjuvant Breast cancer Therapy. The trial is being conducted to see if the use of Nutraceuticals will prevent or reduce Chemotherapy Induced Peripheral Neuropathy (CIPN).

Conditions

  • Peripheral Neuropathy in Breast Cancer Patient

Interventions

DIETARY_SUPPLEMENT

Vitamin D

Vitamin D 2000 IU oral once daily

DIETARY_SUPPLEMENT

Vitamin B6

Vitamin B6 100 mg oral once daily

DIETARY_SUPPLEMENT

Vitamin B12

Vitamin B12 100 mcg oral once daily

DIETARY_SUPPLEMENT

Omega-3 Fatty Acids

Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Katia Tonkin, MD · AHS Cancer Control Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-27
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02795572 on ClinicalTrials.gov